ArthroscopyPhase 4NCT00633386
Effect of Celecoxib Versus Placebo Before and After Knee Surgery on the Overall Use of Analgesics After Surgery
A Phase 4 study testing Celecoxib in people with Arthroscopy, run by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. at 9 sites in United States.
Trial summary
To compare the total analgesic use at 24 hours after arthroscopic knee surgery in patients treated with celecoxib versus placebo. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Arthroscopy
- What is being tested?
- Celecoxib
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 200 participants
- Where
- 9 sitesUnited States
- Study dates
- Feb 2003to Aug 2003
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Diagnosed knee meniscus pathology requiring ambulatory arthroscopic meniscectomy or partial meniscectomy
- Willing to participate in study for 36 hours and come to follow-up visit 7 days post-surgery
Who cannot join
- Osteoarthritis, inflammatory arthritis, or previous fracture of index joint
- Received acetaminophen or low-dose narcotic within 8 hours of surgery
- Have received oral (4 weeks), intramuscular (2 months), intra-articular (3 months) or soft-tissue (2 months) injections of corticosteroids of the first dose of study medication or received intra-articular injections of hyaluronic acid in the index joint within 9 months of the first dose of study medication
Trial locations and contacts
9 sites in 1 country.
9 sites in 1 country
United States9 sites
Pfizer Investigational Site
Baltimore, Maryland, 21218
Pfizer Investigational Site
Charlottesville, Virginia, 22908-0159
Pfizer Investigational Site
Columbia, South Carolina, 29204
Pfizer Investigational Site
Johnson City, Tennessee, 37601
Pfizer Investigational Site
Phoenix, Arizona, 85023
Pfizer Investigational Site
San Antonio, Texas, 78229
Pfizer Investigational Site
Springfield, Massachusetts, 01199
Pfizer Investigational Site
Springfield, Missouri, 65804
Pfizer Investigational Site
St. Petersburg, Florida, 33713
About this study
Official title: A Double-blind, Placebo-Controlled, Randomized, Comparison Study of the Efficacy of Celebrex 400 mg Single Dose Pre and Celebrex 200 mg Post Ambulatory Arthroscopic Knee Surgery for Total Analgesic Use After Surgery
To compare the total analgesic use at 24 hours after arthroscopic knee surgery in patients treated with celecoxib versus placebo.
- Conditions
- Arthroscopy
- Being tested
- Celecoxib, Placebo
- Keywords
- Knee Surgery, Arthroscopic Surgery
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CelecoxibDrug
400 mg oral capsule as a single dose 1 hour prior to surgery and 200 mg oral capsule as a single dose as needed post-surgery
PlaceboOther
Matched placebo
| Study group | Role | What they receive |
|---|---|---|
| A | Experimental | Not described Receives: Drug: Celecoxib |
| B | Placebo comparator | Not described Receives: Other: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Total analgesic use after surgery
Measured: 24 hours
Secondary outcomes (9)
Physical examination
Measured: Day 7
Number and percentage of subjects taking analgesic (hydrocodone bitartrate 5 mg/acetaminophen 500 mg [HC/APAP]) after surgery
Measured: 1, 2, 6, 8, 10, 12, 24, and 36 hours
Time to analgesic use after surgery
Measured: 1, 2, 6, 8, 10, 12, 24, and 36 hours
Cumulative number of HC/APAP tablets taken after first dose of study medication
Measured: 1, 2, 6, 8, 10, 12, 36 hours and Day 2
Vital signs
Measured: Day 7
Patient's Assessment of Knee Pain, according to visual analogue scale at rest and with movement after surgery
Measured: 1, 2, 6, 8, 10, 12, 24 and 36 hours
Change in volumetric measurement of both knees from prior to surgery
Measured: Day 7
Patient Treatment Satisfaction Scales after surgery
Measured: 24 hours
Adverse events
Measured: Day 7
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Mar 2008 (estimated)
- Study startFeb 2003
- Study completionAug 2003
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for ArthroscopyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 200 participants (actual)
Sponsor and investigators
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Pfizer CT.gov Call Center, Study director, Pfizer
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00633386
- Sponsor's protocol ID
- A3191066
- Status last verified
- Feb 2021
- First submitted
- 4 Mar 2008
- Last updated
- 21 Feb 2021
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 21 Feb 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Double-blind, Placebo-Controlled, Randomized, Comparison Study of the Efficacy of Celebrex 400 mg Single Dose Pre and Celebrex 200 mg Post Ambulatory Arthroscopic Knee Surgery for Total Analgesic Use After Surgery
- ClinicalTrials.gov ID
- NCT00633386
- Acronym / sponsor ID
- A3191066
- Conditions
- Arthroscopy
- Keywords
- Knee Surgery, Arthroscopic Surgery
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 200 participants (actual)
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Industry (pharma, biotech, devices)
- Study start
- Feb 2003
- Study completion
- Aug 2003 (actual)
- First posted
- 12 Mar 2008 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To compare the total analgesic use at 24 hours after arthroscopic knee surgery in patients treated with celecoxib versus placebo.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| A | Experimental | Drug: Celecoxib |
| B | Placebo comparator | Other: Placebo |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Diagnosed knee meniscus pathology requiring ambulatory arthroscopic meniscectomy or partial meniscectomy
- Willing to participate in study for 36 hours and come to follow-up visit 7 days post-surgery
Key exclusion criteria (3 listed)
- Osteoarthritis, inflammatory arthritis, or previous fracture of index joint
- Received acetaminophen or low-dose narcotic within 8 hours of surgery
- Have received oral (4 weeks), intramuscular (2 months), intra-articular (3 months) or soft-tissue (2 months) injections of corticosteroids of the first dose of study medication or received intra-articular injections of hyaluronic acid in the index joint within 9 months of the first dose of study medication
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Celecoxib400 mg oral capsule as a single dose 1 hour prior to surgery and 200 mg oral capsule as a single dose as needed post-surgery | Drug | A |
| PlaceboMatched placebo | Other | B |
Primary outcome
Total analgesic use after surgery
Time frame: 24 hours
9 secondary outcomes
Physical examination
Time frame: Day 7
Number and percentage of subjects taking analgesic (hydrocodone bitartrate 5 mg/acetaminophen 500 mg [HC/APAP]) after surgery
Time frame: 1, 2, 6, 8, 10, 12, 24, and 36 hours
Time to analgesic use after surgery
Time frame: 1, 2, 6, 8, 10, 12, 24, and 36 hours
Cumulative number of HC/APAP tablets taken after first dose of study medication
Time frame: 1, 2, 6, 8, 10, 12, 36 hours and Day 2
Vital signs
Time frame: Day 7
Patient's Assessment of Knee Pain, according to visual analogue scale at rest and with movement after surgery
Time frame: 1, 2, 6, 8, 10, 12, 24 and 36 hours
Change in volumetric measurement of both knees from prior to surgery
Time frame: Day 7
Patient Treatment Satisfaction Scales after surgery
Time frame: 24 hours
Adverse events
Time frame: Day 7
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Feb 2021.
- To obtain contact information for a study center near you, click here.Link provided by the sponsor.
Related trials for Arthroscopy
RecruitingPhase 4
Efficacy of Ketorolac for Postoperative Pain Management in Hip Arthroscopy
Femoracetabular Impingement, Hip Arthroscopy
Not yet recruiting
Magnesium Sulphate as an Adjuvant in Combined Costoclavicular Block and Suprascapular Block Versus Interscalene Block for Ambulatory Shoulder Arthroscopy
Postoperative Pain, Shoulder Arthroscopy
Active, not recruiting
Can Perineal Post-Free Traction in Hip Arthroscopy Effectively Reduce Perineal Complications?
Femoroacetabular Impingement Syndrome
Recruiting
Ultrasound-Guided Serratus Posterior Superior Intercostal Plane Block for Analgesia in Arthroscopic Shoulder Surgery
Postoperative Pain, Acute, Shoulder Pain
Not yet recruiting
ESP Versus SPSIP Block for Pain Relief After Shoulder Arthroscopy
Postoperative Pain
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Pfizer CT.gov Call Center study director
Pfizer
9 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Celecoxib in people with Arthroscopy, run by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. at 9 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 21 Feb 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 9 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Total analgesic use after surgery (time frame: 24 hours). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Feb 2021.